Study: HPV vaccine by age 21 a sound public health investment

A new economic analysis shows that the HPV vaccine could be a good financial investment in public health if given to preadolescent girls and women up to age 21. Authors of the study measured the Gardasil vaccine's value by calculating the cost of giving one person an extra healthy year of life and balancing the expense of vaccinations with the benefits of avoiding cancer, death, and related expenses.